摘要
目的:研究冠脉内应用替罗非班对行经皮冠状动脉介入治疗(PCI)的急性心肌梗死(AMI)患者冠脉血流、心功能及血清人软骨糖蛋白39(HCgp-39)、脂蛋白相关磷脂酶A2(Lp-PLA2)、正五聚蛋白3(PTX3)水平的影响。方法:于我院治疗的176例AMI患者被随机均分为常规治疗组(接受常规PCI治疗)与替罗非班组(在常规治疗组基础上加用替罗非班)。观察比较两组治疗前及治疗7d后心肌梗塞溶栓(TIMI)血流分级情况、LVEF、左室舒张末期容积(LVEDV)、左室收缩末期容积(LVESV)、血清HCgp-39、Lp-PLA2、PTX3水平。结果:与常规治疗组比较,治疗后,替罗非班组TIMI 2级比例(10.23%比2.27%)、LVESV[(77.22±8.18)ml比(72.16±13.46)ml]、LVEDV[(135.19±13.96)ml比(129.97±13.46)ml]、血清HCgp-39[(57.33±6.61)μg/L比(54.27±4.26)μg/L]、Lp-PLA2[(190.12±19.55)μg/L比(181.75±20.23)μg/L]、PTX3[(0.76±0.08)μg/L比(0.71±0.08)μg/L]水平均显著降低,TIMI 3级比例(87.50%比97.73%)、LVEF[(47.25±5.45)%比(51.04±5.55)%]均显著升高(P<0.05或<0.01)。结论:冠脉内应用替罗非班可显著改善行PCI的AMI患者冠脉血流、心功能,降低血清HCgp-39、Lp-PLA2、PTX3水平。
Objective:To study influence of intracoronary application of tirofiban on coronary blood flow,cardiac function and serum levels of human cartilage glycoprotein-39(HCgp-39),lipoprotein-associated phospholipase A2(Lp-PLA2)and pentraxins 3(PTX3)in patients with acute myocardial infarction(AMI)undergoing percutaneous coronary intervention(PCI).Methods:A total of 176 AMI patients treated in our hospital were randomly and equally divided into routine treatment group(received routine PCI treatment)and tirofiban group(received tirofiban based on routine treatment group).Thrombolysis in myocardial infarction(TIMI)blood flow grade,LVEF,left ventricular end diastolic volume(LVEDV),left ventricular end systolic volume(LVESV),serum levels of HCgp-39,Lp-PLA2 and PTX3 were observed and compared between two groups before and 7d after treatment.Results:Compared with routine treatment group,after treatment,there were significant reductions in percentage of TIMI grade 2(10.23%vs.2.27%),LVESV[(77.22±8.18)ml vs.(72.16±13.46)ml],LVEDV[(135.19±13.96)ml vs.(129.97±13.46)ml],serum levels of HCgp-39[(57.33±6.61)μg/L vs.(54.27±4.26)μg/L],Lp-PLA2[(190.12±19.55)μg/L vs.(181.75±20.23)μg/L]and PTX3[(0.76±0.08)μg/L vs.(0.71±0.08)μg/L],and significant rise in percentage of TIMI grade 3(87.50%vs.97.73%)and LVEF[(47.25±5.45)%vs.(51.04±5.55)%]in tirofiban group(P<0.05 or<0.01).Conclusion:Intracoronary application of tirofiban can significantly improve coronary blood flow,cardiac function and reduce serum levels of HCgp-39,Lp-PLA2 and PTX3 in AMI patients undergoing PCI.
作者
贺宇峰
田峰
李阳
HE Yu-feng;TIAN Feng;LI Yang(Department of Cardiology,First Hospital of Dandong City,Dandong,Liaoning,118000,China)
出处
《心血管康复医学杂志》
CAS
2022年第1期69-73,共5页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心肌梗死
磷脂酶类
糖蛋白类
Myocardial Infarction
Phospholipases
Glycoproteins
